Published in Ann Oncol on March 19, 2008
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.82
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood (2010) 1.54
Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.07
Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant (2013) 0.86
Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Netw (2015) 0.82
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. Mediterr J Hematol Infect Dis (2015) 0.81
The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J Natl Compr Canc Netw (2011) 0.80
Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant. ISRN Oncol (2014) 0.78
Hodgkin's lymphoma therapy: past, present, and future. Expert Opin Pharmacother (2010) 0.78
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica (2015) 0.77
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients. Oncologist (2015) 0.77
Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant (2015) 0.76
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. Biol Blood Marrow Transplant (2011) 0.75
Next-generation surveillance strategies for patients with lymphoma. Future Oncol (2015) 0.75
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Br J Haematol (2015) 0.75
Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol (2016) 0.75
Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma. Ecancermedicalscience (2010) 0.75
Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab. Ther Adv Hematol (2017) 0.75
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer (2017) 0.75
Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center. Indian J Hematol Blood Transfus (2016) 0.75
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies. Blood Lymphat Cancer (2017) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
The impact of patient-centered care on outcomes. J Fam Pract (2000) 15.07
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
On the Interpretation of Multi-Hit Survival Curves. Proc Natl Acad Sci U S A (1949) 5.96
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Insulin biosynthesis: evidence for a precursor. Science (1967) 5.05
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Biotechnology awareness study, Part 1: Where scientists get their information. Bull Med Libr Assoc (1991) 3.85
A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol (2005) 3.53
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer (1998) 3.36
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) 3.33
Effect of reactive pharmacy intervention on quality of hospital prescribing. BMJ (1990) 3.25
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet (1999) 3.16
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol (1997) 2.71
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Morphine: controlled trial of different methods of administration for postoperative pain relief. Br Med J (1980) 2.55
Aminophylline therapy for acute bronchospastic disease in the emergency room. Ann Intern Med (1991) 2.51
Radiographic interpretation by nurse practitioners in a minor injuries unit. J Accid Emerg Med (1996) 2.44
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol (2005) 2.41
Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial. BMJ (1998) 2.39
Bile acid transformations by microbial strains belonging to genera found in intestinal contents. Acta Pathol Microbiol Scand (1967) 2.33
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis (2009) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol (1999) 2.25
From quantity to quality: the central cardiac audit database project. Heart (1999) 2.23
Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events. J Virol (2001) 2.13
Management of carcinomas of the upper gastrointestinal tract. BMJ (1994) 2.12
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 2.12
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer (1996) 2.11
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol (1996) 2.08
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol (1995) 2.08
Serous cystadenocarcinoma of the pancreas: a new entity? Am J Surg Pathol (1989) 2.03
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study. Eur Heart J (1995) 1.97
EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut (2011) 1.96
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore) (1991) 1.89
Selective cardiac sympathetic blockade as an adjunct to bronchodilator therapy. Thorax (1969) 1.89
Orchiectomy alone for Stage I testicular non-seminoma. A progress report on the Royal Marsden Hospital study. Br J Urol (1983) 1.87
Comparison of "early gastric cancer" in Britain and Japan. Gut (1978) 1.87
Consequences and treatment of ovarian failure after total body irradiation for leukaemia. BMJ (1989) 1.84
The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer (1983) 1.84
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer (2005) 1.81
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet (2001) 1.76
Proliferation of human lymphocytes in culture. Nature (1966) 1.76
A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) (2007) 1.75
The processing peptidase of yeast mitochondria: the two co-operating components MPP and PEP are structurally related. EMBO J (1988) 1.73
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.68
FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer (2000) 1.68
A test for the practical evaluation of male fertility by acridine orange (AO) fluorescence. Fertil Steril (1984) 1.68
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer (2005) 1.68
MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer (2006) 1.68
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer (2002) 1.66
Weight history, glucose intolerance, and insulin levels in middle-aged Swedish men. Am J Epidemiol (1998) 1.66
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol (2012) 1.65
A genetic register for von Hippel-Lindau disease. J Med Genet (1996) 1.61
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut (2003) 1.61
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol (1999) 1.59
Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome. Arthritis Rheum (2001) 1.59
Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer (2007) 1.58
Rapid destructive osteoarthritis: clinical, radiographic, and pathologic features. Radiology (1992) 1.56
A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature (1987) 1.56
Quantitative determination of guanethidine and other guanido-containing drugs in biological fluids by gas chromatography with flame ionization detection and multiple ion detection. Anal Chem (1974) 1.56
The mutational spectrum in Waardenburg syndrome. Hum Mol Genet (1995) 1.55
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
High expression of CD23 in the proliferation centers of chronic lymphocytic leukemia in lymph nodes and spleen. Hum Pathol (1999) 1.55
Carboplatin or cisplatin? Lancet (1988) 1.53